Kuur TherapeuticsProduct Overview
Our Pipeline
Therapy Type
Product
Target Tumors
Target Antigens
Preclinical
Phase 1
Phase 2 & 3
Upcoming Milestones
Autologous
KUR-501
Neuroblastoma
GD2
Complete 4th dose level; 1H 2021
Allogeneic
KUR-502
Hematological
malignancies
CD19
Complete 1st dose level: 1H 2021
Allogeneic
KUR-503
Liver cancer
GPC3
File IND; 2H 2021
KUR-501: Autologous
We are developing a GD2-CAR NKT autologous product (KUR-501) for the treatment of neuroblastoma. A first-in-human study is underway at Baylor College of Medicine (BCM) at Texas Children’s Hospital in Houston, TX.
CAR-NKT in Relapsed or Refractory High Risk GD2+ Neuroblastoma
KUR-501 CAR-NKT Therapy |
|
---|---|
GD2 Biology and Tumor Expression |
|
Unmet Medical Need |
|
Clinical Development Plan |
|
KUR-502: Allogeneic
We are developing an off-the-shelf CD19 targeted allogeneic CAR-NKT product for the treatment of relapsed, refractory CD19-positive malignancy.
Off-the-Shelf CAR-NKT in Relapsed or Refractory CD19+ Malignancies
KUR-502 CAR-NKT Therapy |
|
---|---|
CD19 Biology and Tumor Expression |
|
Unmet Medical Need |
|
Clinical Development Plan |
|
KUR-503: Allogeneic
We are developing an off-the-shelf GPC3 targeted allogeneic CAR-NKT product for the treatment of advanced hepatocellular (liver) cancer.
Off-the-Shelf CAR-NKT Cell Therapy of Hepatocellular Carcinoma (HCC)
KUR-503 CAR-NKT Therapy |
|
---|---|
GPC3 Biology and Tumor Expression |
|
Unmet Medical Need |
|
GPC3 Expression in HCC (Diffuse and Membranous Patterns) |
|
CAR-NKT APPROACH
We are developing a wide range of CAR-NKT cell products to treat different types of highly prevalent tumors. The CAR-NKT cell product candidates include both autologous (KUR-501) and allogeneic (KUR-502 and KUR-503) products.
Kuur Therapeutics Partnering
Kuur Therapeutics is actively seeking licensing and partnering opportunities, drawing on global immunotherapy expertise, to explore and advance the therapeutic possibilities for our NKT cell immunotherapy products.